Oncomine Myeloid MRD NGS Assays (RUO)

More Comprehensive
More Informative
More Streamlined Myeloid MRD Detection

download-flyer-cta

 

Myeloid MRD Assay Overview

The Ion Torrent Oncomine Myeloid MRD Assays (RUO) on the Ion GeneStudio S5 System is a complete NGS testing solution for myeloid measurable residual disease (MRD) research. Highly sensitive AmpliSeq HD technology enables a limit of detection as low as 0.05% allele frequency.

Unlike traditional methods, NGS allows you to obtain informative data across a broad range of biomarkers simultaneously. A DNA and an RNA assay enable comprehensive assessment of genetic alterations, including SNVs, indels, and gene fusions. This streamlined approach to MRD analysis also features a complete informatics and reporting solution that simplifies data analysis and interpretation.

 

 

 

download-infographic-cta

MRD Assay Content Summary

The assays feature DNA and RNA targets for myeloid MRD analysis, allowing simultaneous profiling of single nucleotide variants (SNVs), insertions and deletions (indels), tandem duplications, and key gene fusions.

These carefully curated targets are relevant for all categories of myeloid neoplasms, including Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), and Myeloproliferative Neoplasms (MPN) samples.

dna-panel-icon

DNA Panel

33 genes, including 2 full genes and FLT3-ITDs

Optional 22-amplicon micro-haplotype panel for
chimerism analysis

 

rna-panel-icon

RNA Panel

43 fusion driver genes

990 unique fusions

6 genes with exon splicing variants

5 expression control genes

 

DNA Assay - Gene Targets

ABL1

FLT3†

NRAS

TP53*

ASXL1

GATA2

PHF6

U2AF1

BCOR

IDH1

PTPN11

WT1

BRAF

IDH2

RUNX1

 

CALR

JAK2

SETBP1

 

CBL

KIT

SF3B1

 

CEBPA*

KRAS

SH2B3

 

CSF3R

MPL

SRSF2

 

DNMT3A

MYD88

STAG2

 

EZH2

NPM1

TET2

 

* Full gene sequence.
** FLT3-ITD and TKD.
† Includes partial tandem duplications.

RNA Assay - Fusion Driver Genes Expression Controls Exon Splicing Variants

ABL1

FUS

MYBL1

RARA

ABL1

KMT2A

ABL2

GLIS2

MYH11

RARB

GUSB

RUNX1

ALK

HMGA2

NOTCH1

RARG

PSMB2

NOTCH1

BCL2

JAK2

NTRK1

RET

PUM1

ETV6

BRAF

KAT6A (MOZ)

NTRK2

RUNX1

TRIM27

IKZF1

CCND1

KAT6B

NTRK3

TAL1

 

NTRK1

CREBBP

KMT2A*

NUP214

TCF3

   

CSF1R

KMT2A-PTD

NUP98

TCR4

   

EGFR

MECOM

PAX5

TFE3

   

ETV6

MLLT10

PDGFRA

ZNF384

   

FGFR1

MRTFA (MLK1)

PDGFRB

     

 

Chimerism Analysis

An optional 22-amplicon DNA panel is included for chimerism analysis in post–allogeneic stem cell transplantation (allo-HSCT) research samples.

This innovative NGS technique measures the ratio of donor/recipient DNA down to 0.2% allele frequency. Unlike traditional methods that rely on qualitative analysis, NGS provides digital quantification of allele mixtures to identify low-frequency, disease-associated markers with high sensitivity.

 

 

 

chimerism

 

genestudio-s5-oncomine-thermofisher

 

Streamlined Workflow

The Oncomine Myeloid MRD Assays (RUO) include a fully integrated workflow based on the Ion GeneStudio S5 System.

The entire process can be completed in 2–3 days with roughly 2 hours of hands-on time.

Integrated Informatics and Reporting

The solution includes an integrated analysis pipeline that allows labs to easily analyze samples without needing deep informatics expertise typically required for other assays.

Easily visualize allele frequencies for target genes over a time series using Ion Reporter analysis tools.

 

time tracking-1

Enlarge Chart

 

On-demand Webinar

The-pathologist-logo

Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms.

Dr. Bevan Tandon of Pathline Labs will review ongoing research in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days. He will also share his experience with the upcoming Oncomine Myeloid MRD Assay (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies. Dr. Tandon will share recent analytical data from his team and offer his perspective on the value of NGS in hematopathology studies.

 

 

tandon

Bevan Tandon, MD
Director, Hematopathology and Molecular Pathology, Pathline

watch-on-demand-webinar-cta

 

Additional Resources

FNIH logo2

 

Proud to Partner with the FNIH Biomarkers Consortium

Thermo Fisher Scientific is proud to be a partner on the MRD in AML project, led by the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium. This research initiative is investigating the use of genetic tests to improve the accuracy of measurable residual disease (MRD) detection for Acute Myeloid Leukemia (AML). The project will help to establish MRD as a biomarker in AML and will generate important molecular information that may help inform treatment decisions and ultimately improve patient outcomes in the future.

LEARN MORE

 

Additional Resources

Book a demo or request a quote

Are you ready to speak to a Thermo Fisher Scientific representative? We will be happy to answer all your question and provide a demo.

 

request-contact-cta

 

For Research Use Only. Not for use in diagnostic procedures.